Agoracom: Small Cap Investment - Pluristem Life Systems, Inc. - NEWS/ 9/16 PSTI PRESS RELEASE BELOW..first 3 paragraphs of PR

patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Reply New Message

Back To Forum List View

emma

Rank: Treasurer [?]

Points: 16214 [?]

Votes: 82 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

NEWS/ 9/16 PSTI PRESS RELEASE BELOW..first 3 paragraphs of PR

posted on Sep 16, 2008 02:05AM

Press Release

Source: Pluristem Therapeutics Inc.

Pluristem Presents Final PLX-PAD Efficacy Data Supporting Upcoming IND Submission to the U.S. FDA
Tuesday September 16, 3:24 am ET

PLX-PAD could become an effective therapeutic alternative for diabetics, smokers and others who are at risk of amputation

NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (Nasdaq:PSTI - News)(DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today the successful conclusion of its pre-clinical efficacy studies utilizing PLX-PAD prior to the initiation of human clinical trials. PLX-PAD is Pluristem’s cellular product for the treatment of critical limb ischemia (CLI), the end stage of Peripheral Artery Disease (PAD).

Reply New Message

Back To Forum List View

Please to post a reply